中华皮肤科杂志 ›› 2015, Vol. 48 ›› Issue (8): 559-563.

• 论著 • 上一篇    下一篇

环丙沙星对博来霉素诱导小鼠真皮纤维化的抑制作用

陈艳1,雷铁池1,史赢1,徐世正2   

  1. 1. 武汉大学人民医院
    2. 武汉大学人民医院皮肤科
  • 收稿日期:2014-10-08 修回日期:2015-04-27 出版日期:2015-08-15 发布日期:2015-07-30
  • 通讯作者: 雷铁池 E-mail:tiechilei@126.com
  • 基金资助:

    国家自然科学基金

Inhibitory effect of ciprofloxacin on bleomycin-induced dermal fibrosis in mice

  • Received:2014-10-08 Revised:2015-04-27 Online:2015-08-15 Published:2015-07-30
  • Contact: Tie-Chi LEI E-mail:tiechilei@126.com

摘要:

目的 观察环丙沙星对博来霉素诱导实验性硬皮病小鼠模型真皮胶原合成及致纤维化基因表达的影响。 方法 用博来霉素连续4周皮下注射BALB/c小鼠背部建立实验性硬皮病小鼠模型,随后分为3组,分别给予1%环丙沙星乳膏(环丙沙星组)、2.5%积雪草苷乳膏(积雪草苷组)以及乳膏基质(模型组)连续外擦5周,另外,于小鼠背部皮下注射磷酸盐缓冲液后外擦乳膏基质设立空白对照(对照组)。连续治疗5周后取各组皮肤标本行HE染色、Masson染色、Ⅰ型胶原蛋白以及基质金属蛋白酶1(MMP1)和金属蛋白酶组织抑制因子1(TIMP1)免疫组化分析;同时用半定量逆转录PCR技术测定结缔组织生长因子(CTGF)、转化生长因子 1(TGFβ1)和Smad3基因的表达水平,碱水解-分光光度法测定皮肤羟脯氨酸含量。各组间比较采用单因素方差分析,模型组和各处理组间两两比较采用LSD检验。 结果 博来霉素模型组小鼠注射区真皮厚度[(432.76 ± 93.74) μm]较对照组[(301.69 ± 79.47) μm]明显增厚(P < 0.01),Masson染色可见真皮胶原纤维束粗大致密,排列错乱,符合硬皮病真皮纤维化表现。环丙沙星和积雪草苷组小鼠皮肤胶原总含量、Ⅰ型胶原、TIMP1、MMP1染色强度比模型组明显减少(F值分别为1628.54、33.29、84.82、224.81,均P < 0.01),但真皮厚度改变不明显(均P > 0.05)。与模型组比较,积雪草苷不同程度下调CTGF、TGFβ1和Smad3基因表达水平(均P < 0.05),而环丙沙星仅抑制TGFβ1(P < 0.05)和Smad3(P < 0.05)的表达,对CTGF基因表达作用不明显(P > 0.05)。 结论 环丙沙星可抑制TGFβ1/Smad3通路,改变失衡的MMP1和TIMP1表达,显示抗真皮纤维化作用。

关键词: 模型, 动物

Abstract:

Chen Yan, Lei Tiechi, Shi Ying, Xu Shizheng. Department of Dermatology, Renmin Hospital of Wuhan University, Wuhan 430060, China Corresponding author: Lei Tiechi, Email: tchlei@whu.edu.cn 【Abstract】 Objective To investigate the effects of ciprofloxacin on dermal collagen synthesis and profibrotic gene expressions in an experimental mouse model of scleroderma induced by bleomycin. Methods Experimental mouse models of scleroderma were established by subcutaneous injection of bleomycin into the dorsal skin of 15 BALB/c mice for 4 consecutive weeks. Then, the mouse models were randomly and equally divided into 3 groups to be topically treated with 1% ciprofloxacin cream (ciprofloxacin group), 2.5% asiaticoside cream (asiaticoside group) and cream vehicle (model group) respectively for 5 consecutive weeks. Five mice firstly injected with sterile phosphate buffered saline (PBS) for 4 weeks then topically treated with cream vehicle for 5 weeks served as the blank control group. After the 5-week topical treatment, all the mice were sacrificed, skin specimens were resected from the dorsal skin of them, and subjected to HE staining and Masson staining. Further more, an immunohistochemical assay was performed to measure the expressions of type I collagen (COL-1), matrix metalloproteinase-1 (MMP1) and tissue inhibitor of matrix metalloproteinase-1 (TIMP1), semi-quantitative reverse transcription PCR to quantify the expressions of connective tissue growth factor (CTGF), transforming growth factor-β1 (TGFβ1) and Smad3 genes, and alkaline hydrolysis-spectrophotometry to determine the level of hydroxyproline in skin. Statistical analysis was carried out by one-way analysis of variance and the least significant difference (LSD) test with the SPSS 17.0 software. Results Compared with the blank control group, the model group showed increased dermal thickness at injection sites (432.76 ± 93.74 μm vs. 301.69 ± 79.47 μm, P < 0.01). Masson staining revealed thick and dense collagen bundles in an irregular arrangement in the dermis in the model group, which was consistent with dermal fibrosis in scleroderma. The total content of collagen and staining intensity of COL-1, MMP1 and TIMP1 were all significantly decreased in the ciprofloxacin group and asiaticoside group compared with the model group (F = 1628.54, 33.29, 84.82, 224.81, respectively, all P < 0.01), while no significant changes were observed in dermal thickness (both P > 0.05). Moreover, compared with cream vehicle, asiaticoside down-regulated the expressions of the three profibrotic genes (CTGF, TGFβ1 and Smad3) to different extents (all P < 0.05), while ciprofloxacin only inhibited the expressions of TGFβ1 and Smad3 genes (both P < 0.05) with no significant effect on CTGF gene expression (P > 0.05). Conclusion Ciprofloxacin may counteract dermal fibrosis by inhibiting the TGFβ1/Smad3 pathway and modulating the unbalanced expressions of MMP1 and TIMP1.

中图分类号: 

  • 32-1138/R